Details For Selected Brain Tumor Treatment

Sponsored By

Cedars-Siani Medical Center Brain Tumor Program

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		Phase I Trial of Conditionally Replication-Competent Adenovirus (Delta-24-RGD4C) for recurrent malignant glioma

		Keywords:		Delta-24-RGD replication-competent adenovirus

		Phase:		Phase 1

		Treatment ID#s:		VT1910 ID01-310

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Newly Diagnosed: N Recurrent: Y Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed recurrent malignant glioma

		Last Updated:		04/14/2009

		Tumor Types:		Anaplastic Astrocytoma Glioblastoma Multiforme Gliosarcoma Mixed Glioma Oligodendroglioma High Grade


		Comments:		Rb is inactivated in most glioma cells, and intact in normal cells. Delta-24RGD is an adenovirus that has been engineereed so that it cannot replicate in cells that contain Rb protein. Thus Delta-24 RGD replicates preferentially in cancer cells. In animal experiments, 60% of animals survived until they were euthanized, and microscopic examination of brains showed complete regression of tumor. No observable toxicity was found preclinically. Tumors must be either surgically accessible or accessible for stereotactic injection, and no more than 5 cm in diameter. Physicians must agree that treatment path will not deliver adenovirus to the ventricular system. Patients with Li-Fraumini Syndrome, germline deficit in retinoblastoma gene or related pathways, and immuno-compromised patients are not eligible.

		Treatment Type:		Gene Therapy.

		Contact:		MD Anderson Cancer Center Jan Esenwein Program Coordinator, Brain Tumor Program Contact: Jan Esenwein or Marie Woodward 1515 Holcombe Blvd Houston, TX 77030- Phone:(713)745-2264 Fax: (713)794-4999 Click here to send an email Website: www.mdanderson.org/diseases/braincancer/

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By